LINK: https://us06web.zoom.us/j/85099759729?pwd=Y3GSQZXQX1H0wgxXL7YZZu2mP8pozW.1&from=addon

OBJECTIVES: Upon completion of this activity, the participant should be able to:  (1) Describe the analgesic effectiveness of buprenorphine for chronic non-cancer pain in patients with and without opioid use disorder (OUD), based on the findings of this systematic review and meta-analysis, (2) Analyze the differences in effect size, heterogeneity, and quality of evidence for buprenorphine’s pain-reducing effects in chronic pain patients with OUD versus those without OUD, (3) Identify key limitations of the current evidence base regarding buprenorphine use for chronic pain and explain how these limitations impact clinical decision-making in PM&R and pain medicine practice (Lazaridou et. al., 2020); (4) Identify benefits and risks of utilizing Duloxetine on patients with chronic musculoskeletal pain, (5) Analyze quality of literature or research design in determining efficacy of Duloxetine use (MA, et. al., 2023).

FACULTY DISCLOSURE: Dr. Nweke and Dr. DeMarzo have no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

PLANNER DISCLOSURE: The planners have no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

*Recording of this educational activity, including the use of AI tools, is prohibited.

For information, please contact Alina Manjiyani at [email protected]